Trials / Completed
CompletedNCT01927159
Phase 1 ID93 + GLA-SE Vaccine Trial in BCG-Vaccinated Healthy Adult Volunteers
A Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of the ID93 + GLA-SE Vaccine in BCG-Vaccinated Healthy Adults
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 66 (actual)
- Sponsor
- Access to Advanced Health Institute (AAHI) · Academic / Other
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine the safety, tolerability, and immunogenicity in BCG-vaccinated healthy adult subjects of an investigational vaccine being developed for the prevention of pulmonary tuberculosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ID93 + GLA-SE | |
| OTHER | Placebo |
Timeline
- Start date
- 2013-09-01
- Primary completion
- 2015-07-01
- Completion
- 2015-07-01
- First posted
- 2013-08-22
- Last updated
- 2018-02-01
Locations
1 site across 1 country: South Africa
Source: ClinicalTrials.gov record NCT01927159. Inclusion in this directory is not an endorsement.